Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins
M L Visciano1, L Diomede, M Tagliamonte
1Lab. of Molecular Biology and Viral Oncogenesis & AIDS Reference Center, Istituto Nazionale Tumori Fond. G. Pascale, Naples, Italy.
Vaccine
|May 21, 2011
Summary
Developing an effective HIV-1 vaccine requires eliciting potent neutralizing antibodies. Virus-Like Particles (VLPs) displaying HIV envelope glycoproteins induced significant antibody responses and enhanced neutralization activity when combined.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- Developing an effective preventive HIV-1 vaccine hinges on eliciting potent and broadly neutralizing antibody responses.
- Presenting conformational epitopes on particulate structures like Virus-Like Particles (VLPs) may enhance immune system delivery of antigens.
Purpose of the Study:
- To generate and characterize Virus-Like Particles (VLPs) displaying native HIV Env glycoproteins (gp140 and gp41).
- To assess the immunogenicity and neutralization capacity of these VLPs in preclinical models.
Main Methods:
- HIV Env gp140 and gp41 glycoproteins were expressed on VLPs using a baculovirus system in insect cells.
- Immunogenicity was evaluated in BALB/C mice via intraperitoneal administration, with sera tested for reactivity and neutralization of HIV pseudoviruses.
Main Results:
- VLP-bound gp140 demonstrated appropriate expression and trimeric conformation.
- Sera from immunized mice showed high reactivity against HIV antigens.
- Combined sera from animals immunized with gp140- and gp41-expressing VLPs exhibited additive/synergistic HIV pseudovirus neutralization.
Conclusions:
- Novel VLPs displaying native, trimeric HIV Env glycoproteins were successfully generated.
- These VLPs induced effective antibody responses with significant neutralization activity.
- Combining sera targeting different HIV envelope antigens broadens the scope of targeted viral epitopes, enhancing neutralization.
